188 related articles for article (PubMed ID: 1620543)
1. Two antisense promoters in the immunoglobulin mu-switch region drive expression of c-myc in the Burkitt's lymphoma cell line BL67.
Apel TW; Mautner J; Polack A; Bornkamm GW; Eick D
Oncogene; 1992 Jul; 7(7):1267-71. PubMed ID: 1620543
[TBL] [Abstract][Full Text] [Related]
2. Absence of a paused transcription complex from the c-myc P2 promoter of the translocation chromosome in Burkitt's lymphoma cells: implication for the c-myc P1/P2 promoter shift.
Strobl LJ; Kohlhuber F; Mautner J; Polack A; Eick D
Oncogene; 1993 Jun; 8(6):1437-47. PubMed ID: 8502472
[TBL] [Abstract][Full Text] [Related]
3. The intron enhancer of the immunoglobulin kappa gene activates c-myc but does not induce the Burkitt-specific promoter shift.
Polack A; Strobl L; Feederle R; Schweizer M; Koch E; Eick D; Wiegand H; Bornkamm GW
Oncogene; 1991 Nov; 6(11):2033-40. PubMed ID: 1945409
[TBL] [Abstract][Full Text] [Related]
4. Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.
Jain VK; Judde JG; Max EE; Magrath IT
J Immunol; 1993 Jun; 150(12):5418-28. PubMed ID: 8515068
[TBL] [Abstract][Full Text] [Related]
5. Antiimmunoglobulin inhibition of Burkitt's lymphoma cell proliferation and concurrent reduction of c-myc and mu heavy chain gene expression.
Arasi VE; Lieberman R; Sandlund J; Kiwanuka J; Novikovs L; Kirsch I; Hollis G; Magrath IT
Cancer Res; 1989 Jun; 49(12):3235-41. PubMed ID: 2497974
[TBL] [Abstract][Full Text] [Related]
6. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells.
Jochner N; Eick D; Zimber-Strobl U; Pawlita M; Bornkamm GW; Kempkes B
EMBO J; 1996 Jan; 15(2):375-82. PubMed ID: 8617212
[TBL] [Abstract][Full Text] [Related]
8. The role of immunoglobulin kappa elements in c-myc activation.
Hörtnagel K; Mautner J; Strobl LJ; Wolf DA; Christoph B; Geltinger C; Polack A
Oncogene; 1995 Apr; 10(7):1393-401. PubMed ID: 7731690
[TBL] [Abstract][Full Text] [Related]
9. Combined polymerase chain reaction methods to detect c-myc/IgH rearrangement in childhood Burkitt's lymphoma for minimal residual disease analysis.
Busch K; Borkhardt A; Wössmann W; Reiter A; Harbott J
Haematologica; 2004 Jul; 89(7):818-25. PubMed ID: 15257933
[TBL] [Abstract][Full Text] [Related]
10. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line.
Bemark M; Neuberger MS
Oncogene; 2000 Jul; 19(30):3404-10. PubMed ID: 10918597
[TBL] [Abstract][Full Text] [Related]
11. Differences between Burkitt's lymphomas and mouse plasmacytomas in the immunoglobulin heavy chain/c-myc recombinations that occur in their chromosomal translocations.
Müller JR; Janz S; Potter M
Cancer Res; 1995 Nov; 55(21):5012-8. PubMed ID: 7585544
[TBL] [Abstract][Full Text] [Related]
12. Burkitt's lymphoma cell lines producing truncated mu immunoglobulin heavy chains lacking part of the variable region.
Cogné M; Mounir S; Preud'homme JL; Nau F; Guglielmi P
Eur J Immunol; 1988 Oct; 18(10):1485-9. PubMed ID: 2847931
[TBL] [Abstract][Full Text] [Related]
13. Identification of two distinct MYC breakpoint clusters and their association with various IGH breakpoint regions in the t(8;14) translocations in sporadic Burkitt-lymphoma.
Busch K; Keller T; Fuchs U; Yeh RF; Harbott J; Klose I; Wiemels J; Novosel A; Reiter A; Borkhardt A
Leukemia; 2007 Aug; 21(8):1739-51. PubMed ID: 17541401
[TBL] [Abstract][Full Text] [Related]
14. Level of MYC overexpression in pediatric Burkitt's lymphoma is strongly dependent on genomic breakpoint location within the MYC locus.
Wilda M; Busch K; Klose I; Keller T; Woessmann W; Kreuder J; Harbott J; Borkhardt A
Genes Chromosomes Cancer; 2004 Oct; 41(2):178-82. PubMed ID: 15287031
[TBL] [Abstract][Full Text] [Related]
15. Aberrant c-myc RNAs of Burkitt's lymphoma cells have longer half-lives.
Eick D; Piechaczyk M; Henglein B; Blanchard JM; Traub B; Kofler E; Wiest S; Lenoir GM; Bornkamm GW
EMBO J; 1985 Dec; 4(13B):3717-25. PubMed ID: 3004968
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.
Cutrona G; Carpaneto EM; Ponzanelli A; Ulivi M; Millo E; Scarfì S; Roncella S; Benatti U; Boffa LC; Ferrarini M
Cancer Res; 2003 Oct; 63(19):6144-8. PubMed ID: 14559793
[TBL] [Abstract][Full Text] [Related]
17. A bcl-2/IgH antisense transcript deregulates bcl-2 gene expression in human follicular lymphoma t(14;18) cell lines.
Capaccioli S; Quattrone A; Schiavone N; Calastretti A; Copreni E; Bevilacqua A; Canti G; Gong L; Morelli S; Nicolin A
Oncogene; 1996 Jul; 13(1):105-15. PubMed ID: 8700536
[TBL] [Abstract][Full Text] [Related]
18. Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt's lymphoma.
Gerbitz A; Mautner J; Geltinger C; Hörtnagel K; Christoph B; Asenbauer H; Klobeck G; Polack A; Bornkamm GW
Oncogene; 1999 Mar; 18(9):1745-53. PubMed ID: 10208435
[TBL] [Abstract][Full Text] [Related]
19. Topological organization of the MYC/IGK locus in Burkitt's lymphoma cells assessed by nuclear halo preparations.
Rätsch A; Joos S; Kioschis P; Lichter P
Exp Cell Res; 2002 Feb; 273(1):12-20. PubMed ID: 11795942
[TBL] [Abstract][Full Text] [Related]
20. Mapping chromosomal breakpoints of Burkitt's t(8;14) translocations far upstream of c-myc.
Joos S; Haluska FG; Falk MH; Henglein B; Hameister H; Croce CM; Bornkamm GW
Cancer Res; 1992 Dec; 52(23):6547-52. PubMed ID: 1330296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
